Member Info for violindog

Chester18, perhaps an RNS tomorrow...hence the uptick in activity today ??

Scancell are in the top third of todays share risers.

I know its offen different when you dummy trade......but the "advertised"spread always works against Scancell . Today, with a bit of decent volume , advertised as 7.1%

Hi Moon, yes, a bit of blue 😃. If you don't hold Scancell...now is the time to decide !!

Clearnerworld, obviously BioNtec currently see more potential in Biothesus than Scancell. Will that change on our two upcoming trial results ?? ... its all gone very quiet on any collaboration between Scancell and BioNtec.

EE, thanks for your thoughts and your answers to my questions.

Can he buy at the moment or are Scancell in a closed period ?? If he cant buy i expect that he will be awarded options ?? I wonder if he will be given the same strike price as the other recent appointments .

Chilltime is excelling him/herself on the other board... very positive outlook given for the SP before the year end ...trial results dependant !!

WTP, the large buy was great, but the spread shows that there's currently just no interest in Scancell unfortunately. Everyone sitting on the fence until results...

Had expected some more interest after the huge buy late Friday...

The trading on both Scancell and OBD at EXACTLY 16.35.29 are both linked to Diggle / Vulps ..too much of a coincidence not to be linked. Diggle had fingers in both pies .

Look at OBD, the EXACT thing happened there re the mis qouted share price at the EXACT time !!

Was this coincidence or is the link Diggle ??

As always , excellent research Cleanerworld.

I can't see Scancell’s glymab mentioned in the Pipeline development section ..or am I missing it ?

Yet there are 71, 2 , 1 and 1 buys 🤔

WTP, posting about alternative cancer vaccine companies and the challenges they, in addition to the challenges Scancell faces, is not a reflection of my conviction in Scancell. Yes... as an extremely LTH my conviction waxes and wanes and the competitive field/ funding does worry me .

Morning WTP, all i am pointing out is Scancell are in a similar position to ALL biotechnology companies. Until there is a guaranteed revenue , ALL are dependent on trial results, partnership and fundraising. Scancell are also developing drugs in a competitive arena so they need to become market leaders ASAP .

Hi Berm, their cash runway is to March 25, ours late 2025... and we will be in the same position. They may get $10m from Merck if they decide to licence the drugs under review. They may even get an offer from Merck based on their phase 2 data , after all , merck are supplying the checkpiont for free.. they must like what they see ?

Scancell...we may get ? ?? from the unknown pharma evaluating the glymab and so far that's all that's on the table. We don't know what's happening with Genmab re milestone payments. Both Scancell and Evaxion are both relying on deals or it's back to fundraising again. I think we are in similar positions . Will either of the results result in a deal?? Perhaps this is why Scancell may well press ahead with Scib and not wait for iScib...the competition really is breathing down our neck !

Although a personalised vaccine , I see from that article that there's some competition from EVAXION , who have a supply agreement for the checkpoint from Merck . The company also highlighted that it has entered into an option and license agreement with MSD (which is the tradename of Merck & Co., Inc, Rahway, NJ) for two preclinical vaccine candidates, which we have written about before. The company has collaborated with MSD in the past and we were pleased to see the relationship expand—as it will benefit both the company and potential patients. Under the terms of the agreement, Evaxion grants MSD the option to exclusively license two preclinical vaccine candidates: EVX-B2 and EVX-B3—the former of which is a protein-based candidate for gonorrhea and the latter targeting an undisclosed infectious agent. In return, Evaxion received an upfront payment of $3.2 million and could receive an additional $10 million in 2025, the payment amount dependent on MSD exercising it option to license one or both candidates.

"EVX-01 is a peptide-based neoantigen cancer therapy intended for the first-line treatment of a variety of metastatic and unresectable melanoma. Whilst checkpoint inhibitors have revolutionized the treatment of melanoma, too many patients still die from this cancer. EVX-01 has shown promising clinical results in, with patients benefitting - and even recovering - after receiving the therapy. Evaxion is now conducting a large phase 2 clinical trial with this candidate." In addition, the company reminded investors that its ongoing Phase 2 trial of its personalized cancer vaccine, EVX-01, triggered a 79% tumor-specific response, a substantial increase from the 58% response rate seen in the Phase I trial. As we’ve talked about in previous reports, the AI-Immunology platform of Evaxion showed the promise of improving treatment for patients by being able to “learn” from previous trials and improve upon the treatment as it moves along the approval process. This result is further confirmation of the vast potential that this platform has and illustrates why we continue to have a very positive view on the company.

Specifically in the case of EVX-01, these results, in our view, greatly improve the chance that the treatment will be able to make in through the approval process and reach commercialization stage. Immune responses to such treatments are looked at closely by regulators and these results, according to the company, compare favorably to other personalized cancer neoantigen trials.

######

This sentence is interesting " Immune responses to such treatments are looked at closely by regulators" . If Scancell continue to get excellent results then regulators will love the immune response . As I said, although personalised, we do have competition that's producing excellent results and AI may be stealing the time advantage Scancell has had up to now. Not long to wait before Scancell’s trial results ....and I really hope the management

"The next step is a randomized Phase 2/3 approval study, where half the patients receive only the checkpoints and the other half receive both the checkpoint and the vaccine. "

The randomised 2/3 trial must surely be blinded...ie no one will know if the patient has received SCIB or a placebo in addition to the checkpoints until the trial ends. If, statistically , the patients receiving SCIB have a potential 20-30% enhanced chance of improvement over those patients receiving only checkpionts.... the affect of SCIB would become clearly evident early in the trial. The trial would then need to be halted due to the evident benefit of SCIB.

"In the second cohort, comprising patients with resectable tumors, we observed a significant outcome where 88% of patients did not experience recurrence after being immunized with our drug—a highly encouraging result. We’ve since adopted a quicker approach to demonstrate the vaccine’s efficacy and to pursue regula-tory approval by focusing on the metastatic setting, now incorporating checkpoint inhibitors. These inhibitors enhance the activity and potency of the stimulated T cells within the tumor environment. "

I may have lost track of the reason.....the result of 88% in resectable tumors with no recurrence is amazing... but Scancell are pursuing the metastatic setting with the addition of checkpoints. Scancell, in the article, say its because its a "quicker approach to demonstrate the vaccine’s efficacy and to pursue regula-tory approval " . I get this , but I dont see why they don't peruse this market in tandem. I know its probably related to cost, but Scancell already have trial centres up and running - would it be that much of an additional cost ?? Or is it the strategy to prove the platform in the harder to treat metastatic setting and then take on Moderna further down the road ?? I think LD has eluded to this.

It does make one wonder if Moderna may feel " forced " to bid for Scancell either to adopt the immunobody platform and develop it under their own brand... or mothball it so they can continue to charge exorbitant amounts to health insurance companies for personalised vaccines.